Update… Actinogen Medical (ASX:ACW) receives FDA approval for six-month phase 2b Alzheimer trial
Actinogen Medical (ACW) has received approval from the US Food and Drug Administration (FDA) to proceed with its six-month, Phase 2b, placebo-controlled clinical